Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges

Mariela Mosheva*, Nina Dar, Lee Rima Madi, Avraham Weizman, Doron Gothelf

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Multiple studies have shown that pharmacologic treatments for attention-deficit hyperactivity disorder (ADHD), especially stimulants, are generally effective. There is yet a paucity of empirical data, however, for some common clinical conditions overlooked in the ADHD treatment guidelines. Some examples include: in cases of first line treatment failure, it is unclear whether switching from one type of stimulant to another is beneficial. In cases of comorbid ADHD and severe aggressive/disruptive behavior in children, it is unclear whether the best first-line treatment is stimulants or atypical antipsychotics like risperidone. In cases of ADHD with comorbid anxiety disorders, there is no clear evidence regarding optimal treatment. The objectives of this article are to review these issues and propose possible answers for such clinical dilemmas.

Original languageEnglish
Pages (from-to)300-304
Number of pages5
JournalInternational Clinical Psychopharmacology
Issue number6
StatePublished - 1 Nov 2020


  • aggresive behavior
  • anxiety
  • attention-deficit hyperactivity disorder


Dive into the research topics of 'Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges'. Together they form a unique fingerprint.

Cite this